To investigate the clinical value of cytoreductive surgery（CRS）combined with hyperthermic intraperitoneal chemotherapy（HIPEC）in the treatment of peritoneal pseudomyxoma（PMP）.

A retrospective analysis was given to the case history data of 50 patients diagnosed with PMP who received CRS+HIPEC in the period from March 2017 to March 2018. Relevant domestic and foreign literature was also consulted.

Among the 50 patients，20 were newly diagnosed and 30 had recurrence. 7 cases underwent laparoscopic CRS+HIPEC and 43 cases underwent open CRS+HIPEC. There were 41 cases of low-grade PMP and 9 cases of high-grade PMP. Preoperative tumor markers were elevated in 33 cases and normal in 17 cases. Combined resection of 2 organs was performed in 18 cases，3 organs in 21 cases，and more than 4 organs in 27 cases. The common combined resection organs were colon，small intestine，spleen，stomach，and gallbladder. There were 11 cases of pleural effusion，2 cases of anastomotic leakage，7 cases of intestinal obstruction，3 cases of abdominal abscess，1 case of abdominal hemorrhage，1 case of urinary fistula，4 cases of incision infection，6 cases of lower extremity venous embolism，and 1 case of death. The blood loss was 50~10000 ml（mean，696ml）. The operation time was 4~15 hours（mean，7.8 hours）. The mean hospital stay was 12.4 days（range，5~21 days）. During 1 year follow-up，13 cases had recurrence and 1 case died.

CRS+HIPEC，as a standard diagnosis and treatment technique for PMP，is in urgent need of clinical promotion to improve the current situation of PMP treatment in China.

CRS+HIPEC，as a standard diagnosis and treatment technique for PMP，is in urgent need of clinical promotion to improve the current status of PMP treatment in China.